The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Rationale for Combination Therapy in Multiple Myeloma

Ajai Chari, MD
Published Online:6:51 PM, Tue November 20, 2018

Ajai Chari, MD, associate professor of medicine at the Mount Sinai School of Medicine, discusses the rationale for using combination therapy in patients with multiple myeloma. 

Historically, Chari says that every drug in the treatment landscape has only worked for a short period of time in these patients. Because of this, the agents are combined to increase both response and duration of response, while also decreasing resistance.

Many clinical trials going on now are looking at combination therapies and are showing increased response rates. Chari says these studies are worthy of further attention.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.